An integrated approach combining behavioral assays, neuroimaging, and molecular profiling will be essential to determine whether psychedelics represent viable tools for modifying Tau-associated neurodegenerative processes or trauma-related tauopathies. This evidence concerns the gene MAPT and tauopathy.